Researchers Backpedal From Their Own Risperdal Study
11/20/2013 In the wake of the $2.2 billion settlement by Johnson & Johnson to resolve criminal and civil charges for illegal marketing of the Risperdal antipsychotic pill (more here), two of the authors of a medical paper that was used to inappropriately market the medicine are back peddling from the publication, according to The Chronicle of […]
J&J to Pay at Least $2.5 Billion to Settle Hip Lawsuits
The Wall Street Journal 2013-11-19 The Wall Street Journal reports that Johnson & Johnson has agreed to pay at least $2.5 billion to settle nearly 8,000 hip implant lawsuits In its latest multibillion-dollar legal settlement, Johnson & Johnson has agreed to pay at least $2.5 billion to resolve thousands of lawsuits filed by patients who […]
Sheller in Chronicle of Higher Education on Major Drug Fraud
The Chronicle of Higher Education 2013-11-08 Federal prosecutors on Thursday concluded another multibillion-dollar settlement with a major pharmaceutical company accused of illegally marketing its drugs. In this case, the company was Johnson & Johnson, the total payment was $2.2-billion, and the key drug was Risperdal, which was approved by federal regulators to treat schizophrenia in […]
Sheller in Philadelphia Inquirer on $2.2B Risperdal Settlement
Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) and in 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON – Health-care […]
Sheller settles Whistleblower UMass medical billing fraud case for 66k
The Boston Globe 2013-08-22 Worcester’s UMass Memorial Medical Center has settled fraud charges with the attorney general in a whistleblower case alleging that it improperly sent bills for uninsured patients to a homeless shelter, so it could tap the state for payments. On dozens of occasions, the hospital sent unpaid bills for emergency care to […]
Number One in Pennsylvania for Verdicts and Settlements 2014
2014-12-19 The $2.2 Billion settlement with Johnson & Johnson Leads the Pack The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled by Sheller, P.C. with a $2.2 billion settlement over healthcare giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals. J&J paid the […]
OIG Medicare/Medicaid Whistleblower Fraud Alert and WSJ on physician medical device distributorship
The Wall Street Journal 2013-07-26 The Wall Street Journal today published a front page story on the Department of Justice investigation into fraud in physician-owned distributorships of medical devices. Some instances of this type of Medicare/Medicaid fraud is reported by whistleblowers with representation of whistleblower law firms including Sheller, P.C. Healthcare and other professionals who […]
Sheller Spars With FDA
Lawyer Spars With FDA Over J&J Risperdal Court Documents by Ed Silverman, Pharmalot In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as […]
Sheller on Lawyer Spars With FDA Over J&J Risperdal Court Documents
Pharmalot.com, Pharmaceutical Industry News 2013-07-11 In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as part of ongoing litigation over claims the Johnson […]
Sheller in Philadelphia Inquirer “FDA Slow to Ask J&J for Drug Data”
The Philadelphia Inquirer & “Fierce Pharma” 2013-07-10 The U.S. Food and Drug Administration is dragging its feet in addressing concerns that Johnson & Johnson’s antipsychotic drugs Risperdal and Invega are dangerous, a Philadelphia lawyer says in letters to the federal agency, and the company should allow those alleging harm from the medicines to release information […]
